电话:
+86 (0512) 65829739
传真:
+86 (010) 6788 5057
电子邮件:
orders@antibodies-online.cn

Chemokine (C-C Motif) Ligand 5 (CCL5) Peptide

CCL5 宿主: 合成 BP, WB
产品编号 ABIN8096855
发货至: 中国
Contact our Customer Service for availability and price in your country. Contact Info

Our Local Distributor

中国
北京 101111
No. 88 KeChuang 6th Street
Beijing Economic Technological Development Area
Room 801-803
4A Biotech Co.,Ltd.
Tel +86 (0512) 65829739 传真 +86 (010) 6788 5057

Quick Overview for Chemokine (C-C Motif) Ligand 5 (CCL5) Peptide (ABIN8096855)

抗原

CCL5 (Chemokine (C-C Motif) Ligand 5 (CCL5))

资源

  • 2
  • 1
合成

应用范围

Blocking Peptide (BP), Western Blotting (WB)
  • 原理

    CCL5 Peptide
  • 应用备注

    Optimal working dilution should be determined by the investigator.

    说明

    This is a synthetic peptide designed for use in combination with anti-CCL5 antibody ( ARP37191_T100). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.

    限制

    仅限研究用
  • 状态

    Lyophilized

    溶解方式

    Add 100 µL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.

    缓冲液

    Lyophilized powder

    储存条件

    -20 °C

    储存方法

    For longer periods of storage, store at -20 °C. Avoid repeat freeze-thaw cycles.
  • 抗原

    CCL5 (Chemokine (C-C Motif) Ligand 5 (CCL5))

    背景

    Background Information: Recently, it has been shown that genetic polymorphisms can result in diminished expression of CCL5, which results in increased susceptibility to and progression of infectious diseases. CCL5, together with Th cytokine mRNA expression, is temporally up-regulated during pneumococcal carriage. CCL5 is an essential factor for the induction and maintenance of protective pneumococcal immunity

    Alternative Symbols: SISd, Scya5, RANTES, TCP228, MuRante, MuRantes

    分子量

    10kDa

    基因ID

    20304

    NCBI登录号

    NP_038681

    UniProt

    P30882
You are here: